arches trial overview: adt plus enzalutamide for metastatic hormone-sensitive prostate cancer
Published 5 years ago • 434 plays • Length 1:55Download video MP4
Download video MP3
Similar videos
-
2:37
arches trial: enzalutamide plus adt for mhspc
-
2:18
arches: enzalutamide plus adt in mhspc subgroups
-
1:56
arasens: dialuramide plus adt and docetaxel for metastatic hormone-sensitive prostate cancer
-
3:57
update on arches trial: implications for prostate cancer treatment
-
6:00
arches trial
-
1:30
final os analysis from arches
-
1:35
arches: os by high or low disease volume and progression to mhspc or de novo mhspc
-
2:04
update on overall survival in arches trial
-
3:03
arches post-hoc analyses: efficacy of enza adt in mhspc by pattern of metastatic spread
-
5:11
enzalutamide adt in men with de novo mhspc: the arches trial
-
6:02
update on the arches trial: new indication for enzalutamide in mhspc
-
0:52
mark t. fleming, md, on the arches trial in metastatic hormone-sensitive prostate cancer
-
1:37
arches: os in mhspc who recieved prior adt and reached low psa further treated with enzalutamide
-
3:13
androgen deprivation therapy plus enzalutamide for hormone-sensitive prostate cancer
-
3:18
arches: radiographic progression in the absence of psa progression in patients with mhspc
-
17:44
new approaches to metastatic hormone sensitive prostate cancer
-
3:44
the evolving standard of care for patients with metastatic hormone-sensitive prostate cancer
-
1:18
dr. armstrong discusses arches trial in prostate cancer
-
3:06
titan trial